Context & Business Challenge
As demand from biotech customers increased, the CDMO's quality organization became central to customer trust, manufacturing performance, and long-term differentiation. The company needed quality operations that could scale across sites without slowing the business or weakening regulatory confidence.
Several operating constraints were limiting that goal:
- Manual deviation handling slowed manufacturing teams. Teams were spending too much time drafting, researching, and documenting investigations instead of focusing on the floor.
- SOP interpretation was inconsistent across global sites. Different teams could interpret the same procedure differently, creating avoidable friction, quality risk, and review burden.
- Executive visibility was limited. Quality leadership needed faster insight into site performance, recurring deviation trends, and operational signals across the network.
- Growth required a scalable model. The CDMO needed an approach that could start with four U.S. sites and expand to EU and Asia operations without rebuilding the operating model from scratch.
USDM's Approach
USDM helped the CDMO move from manual, site-specific quality execution toward an AI-enabled digital quality model. The architecture combined Microsoft Azure, OpenAI, a custom knowledge graph built by USDM, and integration with Veeva Quality.
The solution focused on three practical quality capabilities:
- Deviation Investigation Assistant: Accelerates deviation drafting and investigation support so manufacturing teams can spend more time on the floor and less time documenting.
- Quality KPI Assistant: Gives executive leaders real-time visibility into site performance, quality trends, and recurring deviation patterns across all sites.
- SOP Assistant: Provides fast, consistent SOP interpretation at the point of work, supported by embedded FDA regulatory intelligence.
USDM designed the model for regulated operations from the start. That meant pairing AI capability with governance, intended-use clarity, human oversight, controlled data boundaries, quality-system alignment, and a roadmap for scaling across regions.
Technology and Operating Model
The digital quality solution used a governed architecture designed for enterprise life sciences operations:
- Cloud platform: Microsoft Azure.
- Underlying LLM: OpenAI.
- Knowledge graph: Custom-built by USDM.
- Quality system integration: Veeva Quality.
- Rollout model: Four U.S. sites with an EU and Asia roadmap.
Rather than treating AI as a standalone experiment, USDM aligned the solution to the CDMO's operating model. The assistants were designed to support real quality work: investigation drafting, KPI visibility, SOP interpretation, and cross-site quality leadership.
Measured Impact
The engagement showed measurable business value across quality, manufacturing, and executive decision-making:
- Deviation cycle time: approximately 40% reduction.
- SOP review efficiency: approximately 60% improvement.
- Quality and manufacturing productivity: approximately 50% increase.
- Three-year ROI: up to 900%.
- Payback period: as little as 1.6 months.
The Quality KPI Assistant also changed how quality leaders could manage the network. As one VP of Quality described it, simple questions could immediately reveal how each site was performing, giving leadership confidence that recurring issues were visible, addressed, and improving.
What Changed
The CDMO moved from fragmented, manual quality execution toward a more scalable digital quality model. Manufacturing teams gained faster deviation support. Site teams gained more consistent SOP interpretation. Executives gained real-time quality performance visibility. The organization gained a foundation for expanding AI-enabled quality operations across additional regions.
That shift matters for CDMOs because quality excellence is no longer only a compliance requirement. It is part of customer confidence, operational throughput, and competitive differentiation.
Why It Matters for CDMOs
CDMOs operate under pressure from customers, regulators, manufacturing schedules, and global quality expectations. When quality operations rely too heavily on manual documentation, inconsistent interpretation, and delayed visibility, the business pays for it through slower execution and higher operational risk.
AI-enabled quality can change that equation when it is built for regulated environments. The value is not generic automation. The value comes from combining domain-specific quality knowledge, governed architecture, validated workflows, and usable tools that help teams act faster without losing control.
Scale AI-Enabled Quality with USDM
USDM helps CDMOs do exactly that--by delivering AI solutions tailored to regulated environments, grounded in current FDA expectations, and designed to scale quality excellence across global operations. To continue learning from real-world AI success stories, join us at the USDM Life Sciences Summit 2026, where we'll feature additional case studies from innovative customers driving digital transformation in regulated industries, or reach out to discuss your AI use case.